Full Year 2023 Investor Presentation

70 Investor presentation Full year 2023 Oral semaglutide 50 mg in overweight or obesity demonstrated superior body weight reduction in the OASIS 1 phase 3 trial OASIS 1 showed significantly greater weight loss compared to placebo 0 Change in body weight (%) -15 -12 9 -6 ώ Mean baseline body weight: 105.4kg Categorical weight loss % at week 68 100 89.2 -1.8 % of patients 80 88 60 60 40 40 20 20 24.5 74.7 58.5 37.2 11.8 5.3 -17.4 2.4 -18 048 12 16 20 28 36 44 52 60 Time since randomisation (weeks) 0 68 68* ≥5% ≥10% ≥15% ≥20% Oral sema 50 mg Placebo Oral sema 50 mg Placebo Note: Observed data are on-treatment. Week 68* is the body weight change using the trial product estimand Sema: Semaglutide Novo NordiskⓇ

View entire presentation